Inovio Abandons Lassa, MERS Vaccines Shortly After Ending COVID-19 Booster Work

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Two clinical-stage vaccine candidates for Lassa Fever and MERS, funded by CEPI, are being discontinued, but Inovio will continue its focus on DNA medicines for HPV-related conditions and cancer.

Halt
Inovio is halting work on two vaccines partnered with CEPI • Source: Shutterstock

Development setbacks continue for Inovio Pharmaceuticals, Inc. as the Philadelphia-area firm revealed on 17 November that it is ending development of a pair of vaccine candidates – INO-4500 for Lassa Fever and INO-4700 for Middle East Respiratory Syndrome (MERS) – after analyzing data from ongoing trials with funding partner the Coalition for Epidemic Preparedness Innovations (CEPI).

Inovio held its Q3 earnings call on 8 November and the two experimental vaccines were not mentioned during the call...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.